GC373SARS-CoV-2

Aleksandra A Kuznetsova1, Aleksandr P Makhin2, Anatoliy A Bulygin1

  • 1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.

PubMed
概括

针对SARS-CoV-2主要蛋白酶 (Mpro) 的新型皮相聚体抑制剂显示出对抗病毒开发的前景. 这些化合物表现出微分子活性,为未来针对新兴变种的COVID-19治疗提供了潜力.